idebenone
Selected indexed studies
- Idebenone: Clinical Potential Beyond Neurological Diseases. (Drug Des Devel Ther, 2025) [PMID:40951694]
- Idebenone: When an antioxidant is not an antioxidant. (Redox Biol, 2021) [PMID:33254077]
- Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial. (Cell Rep Med, 2024) [PMID:38428428]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Idebenone: Clinical Potential Beyond Neurological Diseases. (2025) pubmed
- Idebenone: When an antioxidant is not an antioxidant. (2021) pubmed
- Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial. (2024) pubmed
- Idebenone in Friedreich's ataxia. (2008) pubmed
- Idebenone vs. rAAV2-ND4 gene therapy in the treatment of Leber's hereditary optic neuropathy: An indirect comparison meta-analysis. (2025) pubmed
- Idebenone attenuates RANKL-induced osteoclastogenesis and improves bone mass in ovariectomized mice. (2025) pubmed
- Idebenone for Leber's hereditary optic neuropathy. (2016) pubmed
- Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? (2015) pubmed
- Idebenone: Novel Strategies to Improve Its Systemic and Local Efficacy. (2018) pubmed
- Therapeutic benefit of idebenone in Leber hereditary optic neuropathy: a systematic review and meta-analysis. (2025) pubmed